Related Experiment Videos
Triplet chemotherapy combinations with new agents: is there a rationale?
1University of Colorado Cancer Center, Health Science Center, Denver 80262, USA.
Seminars in Oncology
|September 5, 1998
Summary
Lung cancer is a leading cause of cancer death. Cisplatin-based chemotherapy improves survival and quality of life for non-small cell lung cancer (NSCLC) patients, establishing it as a standard treatment.
Area of Science:
- Oncology
- Medical Research
Background:
- Lung cancer is a leading cause of cancer death in North America and Europe.
- Non-small cell lung cancer (NSCLC) accounts for 75-80% of lung cancers, often presenting as unresectable disease.
- Current 5-year survival rates for lung cancer are low, highlighting the need for effective treatments.
Purpose of the Study:
- To evaluate the efficacy of cisplatin-based chemotherapy in treating non-small cell lung cancer (NSCLC).
- To compare the effectiveness of new chemotherapeutic agents and combinations against conventional treatments for NSCLC.
Main Methods:
- Meta-analysis of randomized trials involving cisplatin-based chemotherapy in NSCLC patients.
- Review of recent clinical trials assessing new chemotherapeutic agents and combination therapies for NSCLC.
Main Results:
- Cisplatin-based chemotherapy prolongs survival across all stages of NSCLC.
- Adjuvant cisplatin therapy improves outcomes in early-stage disease and combined with radiotherapy in locally advanced disease.
- Cisplatin-based therapy improves quality of life and reduces medical costs for stage III and IV NSCLC patients.
Conclusions:
- Cisplatin-based chemotherapy is the standard treatment for locally advanced or metastatic NSCLC.
- Emerging agents and combination therapies show promise in improving response rates, survival, and reducing toxicity in NSCLC treatment.